Effect of ranolazine on atrial fibrillation in patients with non-ST elevation acute coronary syndromes: Observations from the MERLIN-TIMI 36 trial

Europace

Volumn 17, Issue 1, 2014, Pages 32-37

  Scirica, Benjamin M ^a   Belardinelli, Luiz ^b   Chaitman, Bernard R ^c   Waks, Jonathan W ^a   Volo, Samuel ^a   Karwatowska Prokopczuk, Ewa ^b   Murphy, Sabina A ^a   Cheng, Mei L ^b   Braunwald, Eugene ^a   Morrow, David A ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b GILEAD SCIENCES   (United States)

^c SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Acute coronary syndromes; Anti arrhythmic therapy; Atrial fibrillation; Ranolazine

Indexed keywords

PLACEBO; RANOLAZINE; ACETANILIDE DERIVATIVE; PIPERAZINE DERIVATIVE; SODIUM CHANNEL BLOCKING AGENT;

AGED; ARTICLE; CLINICALLY INSIGNIFICANT ATRIAL FIBRILLATION; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; ELECTROCARDIOGRAPHY MONITORING; FEMALE; FOLLOW UP; HEART ATRIUM FIBRILLATION; HUMAN; MAJOR CLINICAL STUDY; MALE; NON ST SEGMENT ELEVATION ACUTE CORONARY SYNDROME; OUTCOME ASSESSMENT; POST HOC ANALYSIS; PREDOMINANTLY PERSISTENT ATRIAL FIBRILLATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); ACUTE CORONARY SYNDROME; AGE DISTRIBUTION; ATRIAL FIBRILLATION; COMORBIDITY; DRUG ADMINISTRATION; EPIDEMIOLOGY; LONGITUDINAL STUDY; MORTALITY; PLACEBO EFFECT; PREVALENCE; RISK FACTOR; SURVIVAL RATE; TREATMENT OUTCOME; UNITED STATES; VERY ELDERLY;

ACETANILIDES; ACUTE CORONARY SYNDROME; AGE DISTRIBUTION; AGED; AGED, 80 AND OVER; ATRIAL FIBRILLATION; COMORBIDITY; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; LONGITUDINAL STUDIES; MALE; MASSACHUSETTS; PIPERAZINES; PLACEBO EFFECT; PREVALENCE; RISK FACTORS; SODIUM CHANNEL BLOCKERS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 84922443836     PISSN: 10995129     EISSN: 15322092     Source Type: Journal    
DOI: 10.1093/europace/euu217     Document Type: Article

References (27)

1. Steg PG, James SK, Atar D, Badano LP, Blomstrom-Lundqvist C, Borger MA, et al. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J 2012;33:2569-619
2. Lopes RD, Elliott LE, White HD, Hochman JS, Van De Werf F, Ardissino D, et al. Antithrombotic therapy and outcomes of patients with atrial fibrillation following primary percutaneous coronary intervention: results from the APEX-AMI trial. Eur Heart J 2009;30:2019-28
3. Lopes RD, Pieper KS, Horton JR, Al-Khatib SM, Newby LK, Mehta RH, et al. Shortand long-term outcomes following atrial fibrillation in patients with acute coronary syndromes with or without ST-segment elevation. Heart 2008;94:867-73
4. Jabre P, Jouven X, Adnet F, Thabut G, Bielinski SJ,Weston SA, et al. Atrial fibrillation and death after myocardial infarction: a community study. Circulation 2011;123: 2094-100
5. Belardinelli L, Shryock JC, Fraser H. Inhibition of the late sodium current as a potential cardioprotective principle: effects of the late sodiumcurrent inhibitor ranolazine. Heart 2006;92:iv6-iv14
6. Chaitman BR. Ranolazine for the treatment of chronic angina and potential use in other cardiovascular conditions. Circulation 2006;113:2462-72
7. Antzelevitch C, Belardinelli L,ZygmuntAC, Burashnikov A, Di Diego JM, Fish JM, et al. Electrophysiological effects of ranolazine, a novel antianginal agent with antiarrhythmic properties. Circulation 2004;110:904-10
8. Burashnikov A, Antzelevitch C. Role of Late Sodium Channel Current Block in the Management of Atrial Fibrillation. Cardiovasc Drugs Ther 2013;27:79-89
9. Burashnikov A, Di Diego JM, Zygmunt AC, Belardinelli L, Antzelevitch C. Atriumselective sodium channel block as a strategy for suppression of atrial fibrillation: differences in sodium channel inactivation between atria and ventricles and the role of ranolazine. Circulation 2007;116:1449-57
10. Morrow DA, Scirica BM, Karwatowska-Prokopczuk E, Skene A, McCabe CH, Braunwald E. Evaluation of a novel anti-ischemic agent in acute coronary syndromes: design and rationale for the metabolic efficiency with ranolazine for less ischemia in non-ST-elevation acute coronary syndromes (MERLIN)-TIMI 36 trial. Am Heart J 2006;151:1186 e1-9
11. Scirica BM, Morrow DA, Hod H, Murphy SA, Belardinelli L, Hedgepeth CM, et al. Effect of ranolazine, an antianginal agent with novel electrophysiological properties, on the incidence of arrhythmias in patients with non ST-segment elevation acute coronary syndrome: results from the metabolic efficiency with ranolazine for less ischemia in non-ST-elevation acute coronary syndrome thrombolysis in Myocardial Infarction 36 (MERLIN-TIMI 36) randomized controlled trial. Circulation 2007;116: 1647-52
12. Morrow DA, Scirica BM, Karwatowska-Prokopczuk E, Murphy SA, Budaj A, Varshavsky S, et al. Effects of ranolazine on recurrent cardiovascular events in patients with non-ST-elevation acute coronary syndromes: the MERLIN-TIMI 36 Randomized Trial. JAMA 2007;297:1775-83
13. Al-Khatib SM, Sanders GD, Bigger JT, Buxton AE, Califf RM, Carlson M, et al. Preventing tomorrow's sudden cardiac death today: part I: current data on risk stratification for sudden cardiac death. Am Heart J 2007;153:941-50
14. SongY, Shryock JC, Belardinelli L.Anincrease of late sodiumcurrent induces delayed after depolarizations and sustained triggered activity in atrial myocytes. Am J Physiol Heart Circ Physiol 2008;294:H2031-9
15. WuL, Shryock JC, Song Y, Li Y, Antzelevitch C, Belardinelli L. Antiarrhythmic effects of ranolazine in a guinea pig in vitro model of long-QT syndrome. J Pharmacol Exp Ther 2004;310:599-605
16. Ranolazine Implantable Cardioverter-Defibrillator Trial (RAID). 2012. http://clinicaltrials.gov/ct2/show/NCT01215253?term=ranolazine&rank=24 (18 December 2012, date last accessed
17. Verrier RL, Kumar K, Nieminen T, Belardinelli L. Mechanisms of ranolazine's dual protection against atrial and ventricular fibrillation. Europace 2013;15:317-24
18. Scirica BM, Morrow DA, Budaj A, Dalby AJ, Mohanavelu S, Qin J, et al. Ischemia detected on continuous electrocardiography after acute coronary syndrome: observations from the MERLIN-TIMI 36 (Metabolic Efficiency With Ranolazine for Less Ischemia in Non-ST-Elevation Acute Coronary Syndrome-Thrombolysis In Myocardial Infarction 36) trial. J Am Coll Cardiol 2009;53:1411-21
19. Kumar K, Nearing BD, CarvasM, Nascimento BC, Acar M, Belardinelli L, et al. Ranolazine exerts potent effects on atrial electrical properties and abbreviates atrial fibrillation duration in the intact porcine heart. J Cardiovasc Electrophysiol 2009;20: 796-802
20. Miles RH, Passman R, Murdock DK. Comparison of effectiveness and safety of ranolazine versus amiodarone for preventing atrial fibrillation after coronary artery bypass grafting. Am J Cardiol 2011;108:673-6
21. Fragakis N, Koskinas KC, Katritsis DG, Pagourelias ED, Zografos T, Geleris P. Comparison of effectiveness of ranolazine plus amiodarone versus amiodarone alone for conversion of recent-onset atrial fibrillation. Am J Cardiol 2012;110:673-7
22. Koskinas KC, Fragakis N, Katritsis D, Skeberis V, Vassilikos V. Ranolazine enhances the efficacy of amiodarone for conversion of recent-onset atrial fibrillation. Europace 2014;16:973-9
23. Murdock DK, Kaliebe J, Larrain G. The use of ranolazine to facilitate electrical cardioversion in cardioversion-resistant patients: a case series. Pacing Clin Electrophysiol 2012;35:302-7
24. The HARMONY Study. 2014. http://www.gilead.com/news/press-releases/2014/5/gilead-announces-results-from-phase-2-study-showing-reduction-in-atrial-fibrillationburden- with-the-investigational-combination-of-ranolazine-and-lowdose-droneda rone (19 June 2014, date last accessed
25. Ranolazine in Atrial Fibrillation Following An ELectricaL CardiOversion (RAFAELO). http://ClinicalTrials.gov/show/NCT01534962 (14 June 2014, date last accessed
26. Randomized Double Blind Control Trial on Effects of Ranolazine on New Onset Atrial Fibrillation. http://ClinicalTrials.gov/show/NCT01590979 (14 June 2014, date last accessed
27. Suppression Of Atrial Fibrillation With Ranolazine After Cardiac Surgery. http://ClinicalTrials.gov/show/NCT01352416 (14 June 2014, date last accessed